7v1y

From Proteopedia

Serine beta-lactamase-like protein LACTB in complex with inhibitor

PDB ID 7v1y

Drag the structure with the mouse to rotate

Structural highlights

7v1y is a 8 chain structure with sequence from Homo sapiens and Synthetic construct. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	Electron Microscopy, Resolution 2.82Å
Ligands:
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

LACTB_HUMAN Mitochondrial serine protease that acts as a regulator of mitochondrial lipid metabolism (PubMed:28329758). Acts by decreasing protein levels of PISD, a mitochondrial enzyme that converts phosphatidylserine (PtdSer) to phosphatidylethanolamine (PtdEtn), thereby affecting mitochondrial lipid metabolism (PubMed:28329758). It is unclear whether it acts directly by mediating proteolysis of PISD or by mediating proteolysis of another lipid metabolism protein (PubMed:28329758). Acts as a tumor suppressor that has the ability to inhibit proliferation of multiple types of breast cancer cells: probably by promoting decreased levels of PISD, thereby affecting mitochondrial lipid metabolism (PubMed:28329758).^[1]

Publication Abstract from PubMed

Serine beta-lactamase-like protein (LACTB) is a mammalian mitochondrial serine protease that can specifically hydrolyze peptide bonds adjacent to aspartic acid residues and is structurally related to prokaryotic penicillin-binding proteins. Here, we determined the cryoelectron microscopy structures of human LACTB (hLACTB) filaments from wild-type protein, a middle region deletion mutant, and in complex with the inhibitor Z-AAD-CMK at 3.0-, 3.1-, and 2.8-A resolution, respectively. Structural analysis and activity assays revealed that three interfaces are required for the assembly of hLACTB filaments and that the formation of higher order helical structures facilitates its cleavage activity. Further structural and enzymatic analyses of middle region deletion constructs indicated that, while this region is necessary for substrate hydrolysis, it is not required for filament formation. Moreover, the inhibitor-bound structure showed that hLACTB may cleave peptide bonds adjacent to aspartic acid residues. These findings provide the structural basis underlying hLACTB catalytic activity.

Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB.,Zhang M, Zhang L, Guo R, Xiao C, Yin J, Zhang S, Yang M Structure. 2022 May 5;30(5):685-696.e5. doi: 10.1016/j.str.2022.02.007. Epub 2022 , Mar 4. PMID:35247327^[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Keckesova Z, Donaher JL, De Cock J, Freinkman E, Lingrell S, Bachovchin DA, Bierie B, Tischler V, Noske A, Okondo MC, Reinhardt F, Thiru P, Golub TR, Vance JE, Weinberg RA. LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature. 2017 Mar 30;543(7647):681-686. doi: 10.1038/nature21408. Epub 2017 Mar , 22. PMID:28329758 doi:http://dx.doi.org/10.1038/nature21408
↑ Zhang M, Zhang L, Guo R, Xiao C, Yin J, Zhang S, Yang M. Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB. Structure. 2022 May 5;30(5):685-696.e5. PMID:35247327 doi:10.1016/j.str.2022.02.007